Sees FY26 adjusted EBITDA $10M to $20M
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRTX:
- HRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Heron Therapeutics: Undervalued Growth Story Driven by Zynrelef and Aponvie Momentum
- Heron Therapeutics Reports Strong Preliminary Q4 2025 Revenue
- Heron Therapeutics: ZYNRELEF-Led Commercial Inflection and Undemanding Valuation Support Buy Rating and $6 Target
- Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M